Technical analysis of Abivax S.A. (ABVX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Price Performance
| 1 month | -11.04% |
| 3 months | +6.72% |
| Year-to-date | -21.54% |
| 1 year | +30.63% |
52-Week Range
| 52-week High | $148.83 |
| 52-week Low | $69.81 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $122.60 |
| SMA 200 | $119.05 |
| Beta | -0.10 |
| 30-day Volatility (annualised) | 39.7% |
| Price vs SMA 50 | -13.7% |
| Price vs SMA 200 | -11.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $102.42 | |
| 2025-11 | $124.83 | +21.9% |
| 2025-12 | $134.85 | +8.0% |
| 2026-01 | $111.15 | -17.6% |
| 2026-02 | $121.28 | +9.1% |
| 2026-03 | $111.35 | -8.2% |
| 2026-04 | $117.38 | +5.4% |
| 2026-05 | $132.63 | +13.0% |
| 2026-06 | $133.26 | +0.5% |
| 2026-07 | $124.92 | -6.3% |
| 2026-08 | $111.73 | -10.6% |
| 2026-09 | $105.81 | -5.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | $0.88 | $2.29B |
| 2026-09-15 | | $379M |
| 2026-09-15 | $1.03 | $19.67B |
| 2026-09-15 | | $3M |
| 2026-09-15 | | $22M |
| 2026-09-15 | | $7M |
Price
| Price | $106.37 |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | 15.11 |
| EV / EBITDA | -24.97 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 8.75 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 34.93 |